| Company Name: | Allergan, Inc. | | Ticker Symbol: | AGN | | | WWW Address: | www.allergan.com |
| CEO: | David E.I. Pyott | | No. of Employees: | 11,100 |
| Common Issue Type: | CS | | Business Description: | Allergan, Inc., is a multi-specialty health care company develops and commercializes innovative pharmaceuticals, biologics and medical devices.
|
| | | Industry Information: | DRUGS - Drug Manufacturers - Other [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 101.41 |  0.99 | - | - | 100.56 | 101.43 | 99.62 | 2568091 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 30,058.0 | 296.4 | 0.84 | 3.58 | 0.20 | 35.2 | 0.2 | 116.45 - 81.28 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 101.41 | $ | | PE Ratio - LTM | 35.2 | |
| Market Capitalisation | 30,058.0 | mil |
| Latest Shares Outstanding | 296.4 | mil |
| Earnings pS (EPS) | 3.58 | $ |
| Dividend pS (DPS) | 0.20 | ¢ |
| Dividend Yield | 0.2 | % |
| Dividend Payout Ratio | 6 | % |
| Revenue per Employee | 537,602 | $ |
| Effective Tax Rate | 28.1 | % |
| Float | 297.1 | mil |
| Float as % of Shares Outstanding | 99.8 | % |
| Foreign Sales | 2,230 | mil |
| Domestic Sales | 3,478 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 39.00 | % |
| Research & Devlopment (R&D) as % of Revenue | 17.30 | % |
| Gross Profit Margin | 88.9 | % |
| EBITDA Margin | 32.7 | % |
| Pre-Tax Profit Margin | 26.5 | % |
| Assets Turnover | 0.7 | % |
| Return on Assets (ROA) | 12.1 | % |
| Return on Equity (ROE) | 20.9 | % |
| Return on Capital Invested (ROCI) | 15.0 | % |
| Current Ratio | 3.8 | |
| Leverage Ratio (Assets/Equity) | 1.7 | |
| Interest Cover | 28.4 | |
| Total Debt/Equity (Gearing Ratio) | 0.41 | |
| LT Debt/Total Capital | 28.0 | % |
| Working Capital pS | 10.15 | $ |
| Cash pS | 7.42 | $ |
| Book-Value pS | 18.01 | $ |
| Tangible Book-Value pS | 4.31 | $ |
| Cash Flow pS | 4.64 | $ |
| Free Cash Flow pS | 0.23 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 5.63 | |
| Price/Tangible Book Ratio | 23.52 | |
| Price/Cash Flow | 21.9 | |
| Price/Free Cash Flow | 441.4 | |
| P/E as % of Industry Group | 133.0 | % |
| P/E as % of Sector Segment | 101.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Dividend Declared Date | 04/30/2013 |
| Dividend Ex-Date | 05/20/2013 |
| Dividend Record Date | 05/22/2013 |
| Dividend Pay Date | 06/12/2013 |
| Dividend Amount | 50 |
| Type of Payment | Cash Payment |
| Dividend Rate | 0.20 |
| Current Dividend Yield | 0.2 |
| 5-Y Average Dividend Yield | 0.3 |
| Payout Ratio | 6.0 |
| 5-Y Average Payout Ratio | 9.0 |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -2.7 | 95 | 20,476 | 110,483 |
| 4 Weeks | 115.26 | 96.77 | 113.74 | -10.8 | 83 | 28,439 | 568,774 |
| 13 Weeks | 116.45 | 96.77 | 108.02 | -6.1 | 86 | 17,452 | 1,099,466 |
| 26 Weeks | 116.45 | 89.03 | 88.71 | 14.3 | 93 | 16,250 | 2,015,016 |
| 52 Weeks | 116.45 | 81.28 | 88.78 | 14.2 | 89 | 17,165 | 4,274,078 |
| YTD | 116.45 | 92.19 | - | 10.6 | 95 | 17,707 | 1,682,162 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 102.46 | 103.20 | 109.77 | 102.39 | 98.47 | 0.84 | 0.64 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 6.94 | 96.9 | 7.29 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -10.98 | NA | 48.20 |
| R&D | 6.34 | NA | 10.78 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 4.9 | 4.9 | 7.1 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | -94.6 | -94.6 | 18.9 |
| EPS $ | -0.70 | -0.70 | 0.57 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 36.64 |
| Current Ratio | 4.1 |
| Quick Ratio (Acid Test) | 3.4 |
| Liquidity Ratio (Cash) | 2.70 |
| Receivables Turnover | 7.8 |
| Average Collection Period | 46 |
| Working Capital/Equity | 57.6 |
| Working Capital pS | 11.20 |
| Cash-Flow pS | 4.51 |
| Free Cash-Flow pS | 3.43 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 7.19 |
| Financial Leverage Ratio (Assets/Equity) | 1.6 |
| Debt Ratio | 36.4 |
| Total Debt/Equity (Gearing Ratio) | 0.27 |
| LT Debt/Equity | 0.26 |
| LT Debt/Capital Invested | 30.6 |
| LT Debt/Total Liabilities | 45.3 |
| Interest Cover | 25.1 |
| Interest/Capital Invested | 0.79 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 7.45 |
| Tobin's Q Ratio | 3.27 |
| Current P/E Ratio - LTM | 35.20 |
| Enterprise Value (EV)/EBITDA | 16.09 |
| Enterprise Value (EV)/Free Cash Flow | 31.97 |
| Dividend Yield | 0.2 |
| Price/Tangible Book Ratio - LTM | 23.52 |
| Price/Book Ratio - LTM | 5.63 |
| Price/Cash Flow Ratio | 21.9 |
| Price/Free Cash Flow Ratio - LTM | 441.4 |
| Price/Sales Ratio | 5.12 |
| P/E Ratio (1 month ago) - LTM | 39.2 |
| P/E Ratio (26 weeks ago) - LTM | 25.9 |
| P/E Ratio (52 weeks ago) - LTM | 27.4 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 133.0 |
| P/E as % of Sector Segment | 101.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 26.6 |
| PER SHARE FIGURES |
| LT Debt pS | 5.04 |
| Current Liabilities pS | 3.65 |
| Tangible Book Value pS - LTM | 4.31 |
| Book Value pS - LTM | 18.01 |
| Capital Invested pS | 24.80 |
| Cash pS - LTM | 7.42 |
| Cash Flow pS - LTM | 4.64 |
| Free Cash Flow pS - LTM | 0.23 |
| Earnings pS (EPS) | 3.58 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 17.72 |
| Free Cash Flow Margin 5YEAR AVG | 11.97 |
| Net Profit Margin | 19.0 |
| Net Profit Margin - 5YEAR AVRG. | 9.2 |
| Equity Productivity | 0.99 |
| Return on Equity (ROE) | 18.9 |
| Return on Equity (ROE) - 5YEAR AVRG. | 9.3 |
| Capital Invested Productivity | 0.79 |
| Return on Capital Invested (ROCI) | 15.0 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 7.1 |
| Assets Productivity | 0.70 |
| Return on Assets (ROA) | 12.0 |
| Return on Assets (ROA) - 5YEAR AVRG. | 5.7 |
| Gross Profit Margin | 88.9 |
| Gross Profit Margin - 5YEAR AVRG. | 87.6 |
| EBITDA Margin - LTM | 32.7 |
| EBIT Margin - LTM | 27.6 |
| Pre-Tax Profit Margin | 26.4 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 18.5 |
| Effective Tax Rate | 28.1 |
| Effective Tax Rate - 5YEAR AVRG. | 41.2 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 193 |
| Revenue per Employee | 537,602 |
| Net Income per Employee | 102,083 |
| Average Collection Period | 47 |
| Receivables Turnover | 7.8 |
| Day's Inventory Turnover Ratio | 146 |
| Inventory Turnover | 2.5 |
| Inventory/Sales | 4.9 |
| Accounts Payble/Sales | 4.86 |
| Assets/Revenue | 1.43 |
| Net Working Capital Turnover | 1.73 |
| Fixed Assets Turnover | 1.23 |
| Total Assets Turnover | 0.7 |
| Revenue per $ Cash | 2.15 |
| Revenue per $ Plant | 6.81 |
| Revenue per $ Common Equity | 0.99 |
| Revenue per $ Capital Invested | 0.79 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 39.1 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 43.6 |
| Research & Devlopment (R&D) as % of Revenue | 17.0 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 17.0 |
|
|  
| | |  |  | |
| |
